Skip to main content

Table 1 Clinical feature of patients with gastric duplications

From: Clinical features of gastric duplications: evidence from primary case reports and published data

  Literature-based patients (n = 311) Two-centers patients (n = 8) All included patients (n = 319)
Sex Valid = 293 Valid = 8 Valid = 301
 Male 139 (47.44%) 2 (2/8) 141 (46.84%)
Age (years) Valid = 305 Valid = 8 Valid = 313
 Range 0–82 1–55 0–82
 Mean (SD) 20.77 (23.15) 30.63 (20.82) 21.02 (23.10)
Type Valid = 239 Valid = 8 Valid = 247
 Cystic 207 (86.61%) 8(8/8) 215 (87.04%)
 Tubular 32 (13.39) 0(0/8) 32 (12.96%)
Sites Valid = 264 Valid = 8 Valid = 272
 Greater curvature 142 (53.79%) 3 (3/8) 145 (53.30%)
 Lesser curvature 22 (8.33%) 3 (3/8) 25 (9.20%)
  Cardia 18 (6.82%) 0 (0/8) 18 (6.60%)
  Pylorus 47 (17.80%) 1 (1/8) 48 (17.65%)
  AW 5 (1.89%) 1 (1/8) 6 (2.20%)
  PW 30 (11.36%) 0 (0/8) 30 (11.00%)
Other anomalies Valid = 85 Valid = 0 Valid = 85
 Ectopic pancreas 33 (38.82%) 33 (38.82%)
 Other sites duplications 14 (16.47%) 14 (16.47%)
 Pulmonary sequestration 6 (7.06%) 6 (7.06%)
 Congenital heart disease 6 (7.06%) 6 (7.06%)
 Vertebral abnormalities 4 (4.71%) 4 (4.71%)
 Other pancreas anomalies 12 (14.12%) 12 (14.12%)
 Other anomalies 11 (12.94%) 11 (12.94%)
Presentation Valid = 289 Valid = 8 Valid = 297
 Symptomatic 228 (78.89%) 3 (3/8) 231 (77.78%)
  Abdominal pain 105 (46.05%) 0 (0/3) 105 (45.45%)
  Vomiting 105 (45.45%) 0 (0/3) 105 (45.45%)
  Abdominal distension 17 (7.46%) 1 (1/3) 18 (7.79%)
 Gastrointestinal hemorrhage 31 (13.59%) 0 (0/3) 31 (13.42%)
  Fever 15 (6.58%) 0 (0/3) 15 (6.49%)
  Weight loss 23 (10.09%) 0 (0/3) 23 (9.96%)
  Others 19 (8.33%) 2 (2/3) 21 (9.09%)
 Asymptomatic 61 (21.11%) 5 (5/8) 66 (22.22%)
Treatment strategy Valid = 272 Valid = 8 Valid = 280
Surgery 256 (94.12%) 8 (8/8) 264 (94.29%)
 Local resection (LR) 181 (70.70%) 6 (6/8) 187 (70.83%)
 Partial gastrectomy (PG) 63 (24.61%) 2 (2/8) 65 (24.62%)
 Radical resection (RR) 10 (3.91%) 0(0/8) 10 (3.79%)
 LR + RR 2 (0.78%) 0(0/8) 2 (0.76%)
Conservative treatment 16 (5.88%) 0 (0/8) 16 (5.71%)
Follow-up    
Duration (month) Valid = 75 Valid = 2 Valid = 77
 Range 1–120 6–18 1–120
 Mean (SD) 17.51 (19.44) 12 (8.49) 17.36 (19.23)
Outcomes Valid = 75 Valid = 2 Valid = 77
 Recurrence 1 (1.33%) 0 (0/2) 1 (1.30%)
 Metastasis 5 (6.67%) 0 (0/2) 5 (6.49%)
 ANED 61 (81.33%) 2 (2/2) 63 (81.82%)
 AWD 3 (4.00%) 0 (0/2) 3 (3.90%)
 DOD 5 (6.67%) 0 (0/2) 5 (6.49%)